L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection

Case ID:

C10218

C10218: L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection
Value Proposition:
• A broadly protective vaccine against HPV.
• Can be delivered without needles.
• Can be chemically synthesized at low cost.
Technical Details:
Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the United States. Infection by over 15 different oncogenic HPV genotypes is a cause of cervical cancer. Therefore, a low-cost, broadly protective vaccine that can be delivered without needles is urgently needed. JHU scientists have discovered a novel lipopeptide derived from the minor capsid protein L2 of medically-significant HPV genotype and produced by direct synthesis as an approach to generate broadly protective vaccines against HPV-related disease. The L2 lipopeptide can be chemically synthesized at low cost. It can be delivered intranasally without the use of needles.
Looking for Partners:
A broadly protective vaccine against Human papillomavirus infection and any of its sequelae.

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
Multi-Component L2 Vaccine for Prevention of Human Papillomavirus Infection	PCT: Patent Cooperation Treaty	United States	12/740,873	9,138,470	10/12/2010	9/22/2015	11/3/2028	Granted

Direct Link:

https://jhu.technologypublisher.com/technology/60515

Inventors:

Category(s):

Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities,

Get custom alerts for techs in these categories/from these inventors:

Subscribe for JHTV Updates

For Information, Contact:

Vera Sampels

vsampel2@jhu.edu

410-614-0300

Save This Technology:

Bookmark this page

Download as PDF